Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

Zoetis was created in 2013 after splitting off from Pfizer’s animal health division. While it may not seem like a household ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies SAN DIEGO, /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class ...

A large, multicountry European study finds that adults with type 2 diabetes who start empagliflozin experience no increased ...

Scholar Rock's latest trial returned very positive results. Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, ...

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

Mounjaro will soon be available on the NHS across the UK but it's important patients avoid the dangerous 'golden dose' trend ...

A huge surge in Ireland's goods exports in the first quarter of 2025 was partially due to demand for weight loss drugs in the ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Just a year ago, the GenAI buzz in pharma felt like the start of a gold rush. Leaders greenlit pilots. Teams spun up proof-of ...